TriangleADCLEC.syn1 CAR T cells (NCT05748197)
ADCLEC.syn1 CAR T cells trial for Acute Myeloid Leukemia (NCT05748197). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
CAR T cells have not worked well in acute myeloid leukemia, for a stubborn reason: the markers on AML cells also sit on the normal stem cells that make blood. Hit one, and you risk wiping out the marrow.
The idea: require two markers before the cells fire.
At Memorial Sloan Kettering, a patient's T cells receive a deliberately weakened receptor for one AML marker, ADGRE2, and a second receptor for another, CLEC12A, that only supplies the boost. Leukemia stem cells carry both; normal blood stem cells mostly do not. In mice, the design cleared AML and prevented escape while sparing normal blood formation.
A dose-finding study in adults with relapsed or refractory AML. Jae Park leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.